
Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Mogrify Ltd extends Series A financing to $46m
The additional commitment of US$10m that results in US$46m raised was made by the new lead investors Astellas Venture Management and Parkwalk...

Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

BioInnovation Institute Boosts Six Life Science Companies
The Venture House initiative aims at propelling former Venture Lab participants into the next phase of their development. “These six companies have...

Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Germany boosts protein transition with €38m
Germany is set to follow countries such as the Denmark, the UK and the Netherlands, which this year provided massive funding to become world...